Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial
Description
Collaborator VX21-121-105 Study Group: Philipp Latzin, Universitätsklinik für Kinderheilkunde - Pneumologie / Allergologie Julie-von-Jenner-Haus
Publisher DOI
PubMed ID
39756425
Date Issued
2025-03
Publication Type
Article
Language(s)
en
Author(s)
Hoppe, Jordana E | |
Kasi, Ajay S | |
Pittman, Jessica E | |
Jensen, Renee | |
Thia, Lena P | |
Robinson, Philip | |
Tirakitsoontorn, Pornchai | |
Ramsey, Bonnie | |
Mall, Marcus A | |
Taylor-Cousar, Jennifer L | |
McKone, Edward F | |
Tullis, Elizabeth | |
Salinas, Danieli B | |
Zhu, Jiaqiang | |
Chen, Yih-Chieh | |
Rodriguez-Romero, Violeta | |
Sosnay, Patrick R | |
Davies, Gwyneth |
Journal
The Lancet Respiratory Medicine
Publisher
Elsevier
ISSN
2213-2600
Access(Rights)
open.access